This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Reardon G, Navaratnam P, Leonard H.Prevalence and costs of allergic rhinitis in the United States: a comparison of 2005 and 1996 estimates from the Medical Expenditure Panel Survey. 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology: 271 abstr. 1049, 17 Mar 2009
Keith P, Fischer von Weikersthal-Drachenberg KJ.Significant improvements in quality of life following MPL-adjuvanted ultra short course subcutaneous immunotherapy in patients with seasonal grass pollen allergy. 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology: 61 abstr. 219, 14 Mar 2009
Hay J, Jhaveri M, Tangirala M, Kaliner M.Cost and resource utilization comparisons of second generation antihistamines vs. montelukast in treatment of allergic rhinitis: retrospective analysis of a large national insurance claims database. 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology: 213 abstr. 819, 16 Mar 2009
Urdaneta E, Navaratnam P, Friedman HS.The impact of adherence and disease control on resource use and charges in mild persistent asthma patients managed on inhaled corticosteroid inhaler agents. 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology: 42 abstr. 148, 14 Mar 2009
Rights and permissions
About this article
Cite this article
Allergic rhinitis and asthma news from AAAAI. Pharmacoecon. Outcomes News 575, 4 (2009). https://doi.org/10.2165/00151234-200905750-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905750-00007